DOCSLIB.ORG

Vaginitis and Abnormal Vaginal Bleeding

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaginitis and Abnormal Vaginal Bleeding UCSF Family Medicine Board Review March 16, 2014 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: Differential Diagnosis Category Condition Infections Vaginal trichomoniasis (VT) Bacterial vaginosis (BV) Vulvovaginal candidiasis (VVC) MMWR 2010; 59 (RR-12): 1 Skin Conditions Fungal vulvitis (candida, tinea) Contact dermatitis (irritant, allergic) Vulvar dermatoses (LS, LP, LSC) Vulvar intraepithelial neoplasia (VIN) Psychogenic Physiologic, psychogenic Updated Guidelines to Be Published in 2015 CDC 2010: Trichomoniasis Screening and Testing Trichomoniasis: Laboratory Tests Test Sensitivity Specificity Cost Comment • Screening indications – HIV positive women: annually Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) – Consider if “at risk”: new/multiple sex partners, history of STI, Culture +3 (83%) +4 (100%) $$$ Not in most labs inconsistent condom use, sex work, IDU Point of care • Newer assays •Affirm VP III +3 +4 $$$ DNA probe – Rapid antigen test: sensitivity, specificity vs. wet mount •OSOM Rapid +3 (90%) +4 (100%) $$ CLIA waived – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) NaCl suspension +2 (56%) +4 (100%) ¢¢ 1st line • Other testing situations Pap smear +2 +3 n/a Confirm if low – Suspect trich but NaCl slide neg culture or newer assays prevalence – Pap with trich confirm if low risk • Consider retesting 3 months after treatment Accuracy data: Huppert CID 2007 CDC 2010: VT Treatment CDC 2010 : VT Treatment Failure • • Recommended regimen Re-treat with either – – Metronidazole 2 grams PO single dose Tinidazole 2 g PO single dose – – Tinidazole 2 grams PO single dose Metronidazole 500 mg PO BID x 7 days • • Alternative regimen (preferred for HIV infected women) If repeat failure, treat with – – Metronidazole 500 mg PO BID x 7 days Metronidazole 2 grams PO x 3-5 days • Metronidazole safe at all gestational ages • If repeat failure – Limited pregnancy data on Tinidazole – Tinidazole 2-3 g PO plus 1-1.5 g vaginally x14 days • Treat sex partner(s) • Arrange for susceptibility testing: Call CDC!! • Targeted screening for other STIs: GC, Ct, syphilis, HIV – 770-488-4115 BV: Pathophysiology BV: Sexually Associated or Transmitted ? • • Non-inflammatory bacterial overgrowth “Sexually associated” in heterosexuals – – 100 x increase Gardnerella vaginalis Rare in virginal women – – 1000 x increase in anaerobes Greater risk of BV with multiple male partners – – More pathogen types ( Mobiluncus, Mycoplasma) Condom use decreases risk • But Suppression of H 2O2-producing Lactobacillus crispatus and L. – jensenii No BV carrier state identified in men – • >50% women carry G. vaginalis in their vaginal flora Treatment of male partner does not affect recurrences – • Women having sex with women (WSW) Bacterial “C/S” of vaginal fluid doesn’t help in the – diagnosis of BV….or of any other vaginal infection Infected vaginal fluid between women causes BV – BV concurrence in WSW couples suggests horizontal transmission BV: Clinical Diagnosis Characteristic Discharge With BV • Amsel Criteria : 3 or more of – Homogenous white discharge – Amine odor (“whiff” test) – pH > 4.5 (most sensitive) – Clue cells > 20% (most specific) • Spiegel criteria Nugent score – Gram stain with •Few or no gram positive Lactobacillus spp. •Excess of gram negative morphotypes BV: Clue Cells on Saline Suspension NOT a clue cell NaCl Slide: BV >20% of Saline: 40X epithelial objective cells are Clue cells clues Reduced Source : Seattle STD/HIV Lactobacilli Prevention Training Center at the University of Washington Ragged cell border NOT a clue cell BV: Laboratory Tests Test Sensit Specif Cost Comment Nugent score +4 +4 ¢¢ Labor intensive Point of care tests Affirm VP III +4 +3 $$$ DNA probe OSOM BV Blue +3 +3 $$ CLIA moderate G vag PIP +2 +3 $$$ CLIA moderate pH + amines +2 +2 $ CLIA waived Amsel criteria +3 +2 ¢¢ 1st line Pap smear +1 +2-3 n/a Coccobacilli Who Should Be Tested for BV? CDC 2010: BV Treatment • Routine screening not indicated Recommended regimens • Diagnostic testing – Metronidazole 500 mg PO BID x 7 days – Check discharge, amines, vaginal pH, clue cells – Metronidazole gel 0.75% 5g per vagina QD x 5 days • Microscopy not available or inconclusive – Clindamycin 2% cream 5g per vagina QHS x 7 days – Affirm VP III Alternative regimens – OSOM BV Blue – Tinidazole 2 g PO QD for 3 days – G vaginalis PIP, pH + amine test cards – Tinidazole 1 g PO QD for 5 days • “Shift in vaginal flora” on cervical cytology – Clindamycin 300 mg PO BID x 7 days – No consensus, but poor correlation with BV…most experts – Clindamycin ovules 100 mg per vagina QHS x 3 days recommend no further follow up CDC 2010: VVC Classification CDC 2010: Recurrent BV • Uncomplicated VVC (80-90%) • Consider suppression with metronidazole vaginal gel twice – Sporadic or infrequent VVC, and weekly for 4-6 months (after full initial treatment) – Mild-to-moderate VVC, and • No evidence yet to support use of probiotics – Likely to be Candida albicans, and • Don’t douche…with anything! – Immunecompetent • • Use of condoms by male partners may reduce recurrences Complicated VVC (10-20%) – • Clean sex toys (or use condoms) between uses Recurrent VVC, or – • Avoid vaginal insertion after anal insertion of a finger or Severe VVC, or – penis Non-albicans candidiasis, or – Uncontrolled DM, immunosuppression, pregnancy VVC: Laboratory • KOH suspension Candidal − C. albicans: pseudohyphae and blastospores (buds) Pseudo- − C. glabrata: blastospores only hyphae • NaCl suspension : many WBC, normal lactobacillus • pH : 4-6 10% KOH: 10X objective • Amine test : negative • Confirmatory tests Source - : Seattle STD/HIV Point of care test: Affirm VP III Prevention Training Center - Candida culture ( not: fungus culture) at the University of - Candida PCR Washington Yeast CDC: Treatments for VVC PMNs and pseudohyphae Yeast Drug OTC Prescription Pseudohyphae Length of 7 d 3 d 1 d 7 d 3 d 1 d Treatment Saline: 40X PMNs Yeast Butoconazole X objective buds Clotrimazole X X X Miconazole X X X Source : Seattle STD/HIV Prevention Terconazole X X Training Center at the Tioconazole X X University of Washington Squamous epithelial cells Fluconazole (PO) X CDC 2010: Uncomplicated VVC Treatments CDC 2010: Complicated VVC Treatment • Non-pregnant women Severe VVC – 3 and 7 day topicals have equal efficacy and price • Advanced findings: erythema, excoriation, fissures – Offer either : 1 or 3 day topical or oral fluconazole • Topical azole therapy for 7-14 days, or • Topical: quickly soothing, but inconvenient Compromised host • Oral: convenient, but effect is not immediate • Topical azole treatment for 7-14 days • If first treatment course fails • Fluconazole 150 mg PO; repeat Q3 days 1-2 times – Re-confirm diagnosis (r/o dual infection) Pregnancy – Treat with an alternate antifungal drug • Topical azoles for 7 days – Perform Candida culture to confirm and speciate • No role for nystatin, candicidin CDC 2010: Complicated VVC Treatment CDC 2010: Complicated VVC Treatment Recurrent VVC (RVVC) • Recurrent VVC: Treatment • > 4 episodes of symptomatic VVC per year – Treat for 7-14 days of topical therapy or fluconazole 150 o • Most women have no predisposing condition mg PO q 72 x3 doses , then – – Screen for HIV and Type 2 DM if risk factors Maintenance therapy x 6 months • – Partners are rarely source of infection Fluconazole 100-200 mg PO 1-2 per week • Itraconazole 100 mg/wk or 400 mg/month • Confirm with Candidal culture before maintenance therapy; • also checks for non-albicans species Clotrimazole 500 mg suppos 1 per week • • Early treatment regimen: self-medication 3 days with onset Boric acid 600 mg suppos QD x14, then BIW • of symptoms Gentian violet: Q week x2, Q month X 3-6 mo Vaginal Bleeding…What’s Normal? Abnormal Vaginal Bleeding (AVB) Symptom Definitions • Onset of menses • – By 16 years old with 2o sex characteristics Abnormal amount of bleeding – – Start evaluation at 14 years of age if no sexual Menorrhagia (hypermenorrhea) • development Prolonged duration of menses • • Cycle length: 24-35 days Increased amount of bleeding per day – • Menstrual days: 2-7 days Hypomenorrhea • • Menstrual flow: 20-80 cc. per menses Shorter menses • – Average flow: 35 cc. per menses Less flow per day Abnormal Vaginal Bleeding Abnormal Vaginal Bleeding (AVB) Symptom Definitions Symptom Definitions • Abnormal timing of bleeding: REGULAR Cycles • Abnormal amount of bleeding – – Menorrhagia (hypermenorrhea) Polymenorrhea: cycle length < 24 days •Prolonged duration of menses 7 days 14 days 7 days14 days 7 days •Increased amount of bleeding per day – Intermenstrual bleeding: (IMB) – 21 days Hypomenorrhea 7 days 7 days 7 days • Shorter menses – Post-coital bleeding (PCB) •Less flow per day 7 days 7 days 7 days intercourse intercourse Abnormal Vaginal Bleeding Abnormal Vaginal Bleeding Symptom Definitions Symptom Definitions • Abnormal timing of bleeding: IRREGULAR Cycles • Decreased frequency of bleeding – Metrorrhagia – Oligomenorrhea • Light “irregularly irregular” bleeding •No bleeding 36 days- 3 months – Menometrorrhagia – Amenorrhea • Heavy “irregularly irregular” bleeding •No bleeding for… 7 days 3 2 10 days 2 4 3 cycle intervals or 6 months (in oligomenorrheic women) – Post-menopausal: bleeding >1 year after menopause Abnormal Vaginal Bleeding (AVB) Hx, PE, Abnormal Vaginal Preg test Bleeding
Load more

Recommended publications
  • Outcomes of in Vitro Fertilization Cycles Following Fertility-Sparing Treatment in Stage IA Endometrial Cancer
    Archives of Gynecology and Obstetrics (2019) 300:975–980 https://doi.org/10.1007/s00404-019-05237-2 GYNECOLOGIC ONCOLOGY Outcomes of in vitro fertilization cycles following fertility‑sparing treatment in stage IA endometrial cancer Myung Joo Kim1 · Seung‑Ah Choe1 · Mi Kyoung Kim2 · Bo Seong Yun2 · Seok Ju Seong2 · You Shin Kim1 Received: 19 April 2019 / Accepted: 28 June 2019 / Published online: 22 August 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose This study aimed to present cases involving in vitro fertilization (IVF) cycles in patients with stage IA endometrial adenocarcinoma (EC) who underwent fertility-sparing conservative treatment. Methods Twenty-two patients who underwent IVF cycles in a single fertility center between May 2005 and February 2017 after progestin treatment for stage IA EC were chosen for this study. Outcomes of IVF cycles were analyzed retrospectively. Results Women of a median age of 34 years (range 26–41 years) underwent a total of 49 embryo transfers within an aver- age of 2 months after their last progestin treatment. The clinical pregnancy rate per transfer was 26.5%, implantation rate was 16.7%, and live birth rate was 14.3%. The cumulative clinical pregnancy rate was 50% (11/22), resulting in 6 live births (27.3%) within 3 cycles of embryo transfer. The median endometrial thickness on the day of human chorionic gonadotro- pin injection in 34 fresh cycles was 9.0 mm (range 4–10 mm) in live births, 7.5 mm (range 6–9 mm) in miscarriages, and 6.0 mm (range 4–15 mm) in no pregnancy cases.
    [Show full text]
  • Pelvic Inflammatory Disease (PID) Brown Health Services Patient Education Series
    Pelvic Inflammatory Disease (PID) Brown Health Services Patient Education Series the uterine lining to treat abnormal What is PID? bleeding) PID (pelvic inflammatory disease) is ● PID risk from insertion of an IUD inflammation caused by infections ascending (intrauterine device) – occurs in the first 3 weeks post insertion from the vagina or cervix to the upper genital ● Abortion tract. This includes the lining of the uterus, the ovaries, the fallopian tubes, the uterine wall Why is it important to treat PID? and the uterine ligaments that hold these ● structures in place. PID is the most common serious infection of women aged 16 to 25 years What causes it? of age ● Untreated pelvic infections may cause Most cases of PID are caused by sexually adhesions in the fallopian tubes, which transmitted infections (STIs). The disease can be may lead to infertility caused by many different organisms or ● 1 in 4 women with acute PID develop combinations of organisms, but is frequently future problems such as ectopic caused by gonorrhea and chlamydia. Although pregnancy or chronic pelvic pain from Bacterial Vaginosis (BV) is associated with PID, adhesions whether the incidence of PID can be reduced by What are the symptoms? identifying and treating people with vaginas with BV is unclear. If you notice abnormal ● Painful intercourse could be the first discharge and a fishy vaginal odor (signs of BV) sign of infection ● you should be evaluated at Health Services. Pain and tenderness involving the lower abdomen, cervix, uterus and ovaries PID may also occur following procedures that ● Fever and chills create an open wound where infectious ● Nausea and/or diarrhea organisms can more easily enter, such as: ● Abnormal vaginal bleeding or discharge ● Biopsy from the lining of the uterus Early treatment can usually prevent these ● D & C (dilation and curettage – a problems.
    [Show full text]
  • Prevalence of Malignant Uterine Pathology in Utero-Vaginal Prolapse After Vaginal Hysterectomy
    Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology PelviperineologyORIGINAL Pelviperineology ARTICLE Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology Pelviperineology DOI: 10.34057/PPj.2020.39.04.006 Pelviperineology 2020;39(4):137-141 Prevalence of malignant uterine pathology in utero-vaginal prolapse after vaginal hysterectomy EDGARDO CASTILLO-PINO1, VALENTINA ACEVEDO1, NATALIA BENAVIDES1, VALERIA ALONSO1, WASHIGNTON LAURÍA2 1Department of Obstetrics and Gynaecology, Urogynaecology and Pelvic Floor Unit, School of Medicine, University of the Republic, Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay 2Department of Obstetrics and Gynaecology, School of Medicine, University of the Republic, Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay ABSTRACT Objective: The aim of this study was to establish the prevalence of malignant uterine pathology after vaginal
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • Women's Health: a Guide to Preventing Infections, Bacterial
    Women’s Health: A Guide to Preventing Infections Bacterial vaginosis, or BV, is a common vaginal infection in women. It is the most common vaginal infection in women of childbearing age, including pregnant women. Bacterial Vaginosis (BV) While it is not a sexually transmitted disease (STD), The risk of BV is higher if you: some sexual behaviors increase the chances for BV. u Have a new sex partner or multiple sex partners. Women who have never had sex can also have BV. u Douche. u Do not use condoms. How is it spread? u Have a female sexual partner with BV. The vagina contains many different types of bacteria. Normally, there are large numbers of “good” bacteria that keep the number of “harmful” bacteria very low. BV is more common in lesbian Bacterial vaginosis occurs when this balance is upset and bisexual women than in and there are more “harmful” bacteria than “good” other women. The reason for bacteria. The cause of BV is not fully understood. this is unknown. Veterans Health Administration 2012 Women’s Health: Bacterial Vaginosis (BV) What are signs of BV in women? Women with BV may have few or no signs of infection. Some women with BV have: u Increased vaginal discharge: Often watery. Gray or white in color. Sometimes has an unpleasant, fish-like odor, especially after sex. u Itching or irritation in the vaginal area. u Burning during urination. How do you know if you have BV? BV can be diagnosed during a medical exam. To check for BV, your health care provider looks for signs of infection and collects a sample of vaginal fluid for lab tests.
    [Show full text]
  • Chronic Unopposed Vaginal Estrogen Therapy
    October, 1999. The Rx Files: Q&A Summary S. Downey BSP, L.D. Regier BSP, BA Chronic Unopposed Vaginal Estrogen Therapy The question of whether progestagen opposition is required in a patient on chronic vaginal estrogen is controversial. The literature is not clear on this matter and the SOGC conference on Menopause did not reach a consensus. Endometrial hyperplasia is directly related to the dose and duration of estrogen therapy. The PEPI study showed that 10 per cent of women taking unopposed estrogen (equivalent to 0.625 mg CEE) will develop complex or atypical endometrial hyperplasia within 1 year. With long-term HRT, it is now considered standard practice to add progestagen opposition to oral estrogen therapy in women with an intact uterus. The case is less clear for vaginal estrogen therapy. The makers of Premarinâ vaginal cream indicate their product is for short term management of urogenital symptoms and the monograph clearly states "precautions recommended with oral estrogen administration should also be observed with this route". In one recent study looking at "Serum and tissue hormone levels of vaginally and orally administered estradiol" (Am J Obstet Gynecol 1999;180:1480-3), serum levels were 10 times higher after vaginal vs. oral administration for exactly the same dose while endometrial concentrations were 70 times higher. This suggests that in some cases very little estrogen is required vaginally to produce significant serum levels and there may be preferential absorption into the endometrium. Hence equivalent vaginal doses may sometimes be much lower on a mg per mg basis compared to oral, largely because of bypassing the "first pass" effect.
    [Show full text]
  • Vaginitis No Disclosures Related to This Topic
    Vaginitis No disclosures related to this topic Is the wet prep out of the building? Images are cited with permissions Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health Center Michigan Medicine Ann Arbor, Michigan Women with vaginal discharge Is vaginal discharge ever “normal ”? Normal 30% Bacterial vaginosis 23-50% Few primary studies and most of low quality. Candida vaginitis 20-25% Quantity and quality of vaginal discharge varies considerably across women and during the Mixed 20% menstrual cycle. Desquamative inflammatory 8% Symptom of vaginal discharge is non-specific. Vaginitis Vaginal discharge is often thought to be vaginitis. Trichomoniasis 5-15% Vaginal symptoms are very common Patient with chronic vaginal discharge Presence or absence of a microbe corresponds poorly with the presence or absence of 17 year old GO complains of lots of heavy white symptoms. vaginal discharge which is bothersome. No agreement about timing, color or Regular periods, denies any sexual activity. characteristics of discharge among women with Numerous evaluations for STI’s, all negative. vaginal discharge Treated for vaginal candida, BV and trich Most women think vagina should be “dry ”. although there was no evidence for any Vaginal wetness may be normal . infection and did not resolve discharge. Schaaf et al. Arch Intern Med 1999;150. Physiologic vaginal discharge 17 year old Chronic vaginal Patients and providers may consider that a thick discharge white discharge is most frequently caused by candidiasis. Always wears a pad May lead to repeated use of unnecessary antifungal therapy and prompt concerns of Diagnosis? recurrent infection if not resolved.
    [Show full text]
  • Changes Before the Change1.06 MB
    Changes before the Change Perimenopausal bleeding Although some women may abruptly stop having periods leading up to the menopause, many will notice changes in patterns and irregular bleeding. Whilst this can be a natural phase in your life, it may be important to see your healthcare professional to rule out other health conditions if other worrying symptoms occur. For further information visit www.imsociety.org International Menopause Society, PO Box 751, Cornwall TR2 4WD Tel: +44 01726 884 221 Email: [email protected] Changes before the Change Perimenopausal bleeding What is menopause? Strictly defined, menopause is the last menstrual period. It defines the end of a woman’s reproductive years as her ovaries run out of eggs. Now the cells in the ovary are producing less and less hormones and menstruation eventually stops. What is perimenopause? On average, the perimenopause can last one to four years. It is the period of time preceding and just after the menopause itself. In industrialized countries, the median age of onset of the perimenopause is 47.5 years. However, this is highly variable. It is important to note that menopause itself occurs on average at age 51 and can occur between ages 45 to 55. Actually the time to one’s last menstrual period is defined as the perimenopausal transition. Often the transition can even last longer, five to seven years. What hormonal changes occur during the perimenopause? When a woman cycles, she produces two major hormones, Estrogen and Progesterone. Both of these hormones come from the cells surrounding the eggs. Estrogen is needed for the uterine lining to grow and Progesterone is produced when the egg is released at ovulation.
    [Show full text]
  • Bacterial Vaginosis
    Bacterial Vaginosis What is bacterial vaginosis? Bacterial vaginosis (BV) is a change in the normal balance of bacteria in the vagina with overgrowth of bad bacteria. It is the most common cause of vaginal discharge and odor. What bacteria are supposed to be in the vagina? Lactobacilli are the good bacteria of the vagina (probiotics). They produce lactic acid keeping the vaginal mildly acidic thereby preventing overgrowth of bad bacteria. How common is bacterial vaginosis? Bacterial vaginosis is the most common vaginal infection in women ages 15-44. 29% of women age 15-49 have had bacterial vaginosis. How is bacterial vaginosis spread? Researchers do not know the cause of BV or how some women get it, but we do know the infection is more common in sexually active women. How can I avoid getting bacterial vaginosis? The following basic prevention steps may help lower your risk of developing BV: use condoms with sex, limit your number of sex partners, stop douching, increase probiotics in your diet or take oral probiotic capsules containing Lactobacilli. How do I know if I have bacterial vaginosis? Many women (84%) with BV do not have symptoms. If you do have symptoms, you may notice a thin white or gray vaginal discharge, odor, pain, itching, urinary urgency and frequency or burning in the vagina or with urination. How is bacterial vaginosis treated? Traditional treatment is with vaginal or oral antibiotics such as metronidazole or clindamycin. Male sex partners of women diagnosed with BV do not need to be treated. Are there any natural remedies for BV? In addition to probiotics, studies have shown effective treatment with garlic tablets by mouth for seven days, boric acid vaginal suppositories nightly for two weeks and hydrogen peroxide 3% 30ml vaginal washings nightly for seven days.
    [Show full text]
  • Heavy Menstrual Bleeding
    25/06/2018 Definition • Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional and/or material quality of life. Heavy Menstrual Bleeding (HMB): Replaced ‘menorrhagia’ Objective definition of HMB >80mL/ cycle or duration of >7 days Causes and Management • It can occur alone or in combination with other symptoms (e.g. intermenstrual bleeding, pelvic pain, pressure symptoms) Dr. William (Wee-Liak) Hoo, MD MRCOG Consultant Gynaecologist Prevalence King’s College Hospital NHS FT • The prevalence of HMB in objective studies (9 to 14%) and subjective studies 20 to 52%) in studies based on subjective assessment. • In the UK, almost 1.5 million women consult their General Practitioners UKCPA Women’s Health Group Masterclass (GPs) each year with menstrual complaints and the annual treatment cost Friday 22nd June 2018 exceeds £65 million. Causes • Uterine: Uterine fibroids (dysmenorrhoea, palpable mass, pressure symptoms) Adenomyosis (dysmenorrhoea, subfertility) Endometrial polyps (intermenstrual bleeding) Pelvic inflammatory disease (PID)/ infection (vaginal discharge, pelvic pain, intermenstrual and postcoital bleeding and pyrexia) Malignancy or atypical hyperplasia (irregular/ postcoital/ intermenstrual bleeding, pelvic pain, weight loss). • Ovarian: Polycystic ovary syndrome (acne, hursuitism) • Systemic diseases: Hypothyroidism (fatigue, constipation, cold intolerance and hair and skin changes) Coagulation disorders (e.g. von Willebrand disease) Liver
    [Show full text]
  • The Microbiota Continuum Along the Female Reproductive Tract and Its Relation to Uterine-Related Diseases
    ARTICLE DOI: 10.1038/s41467-017-00901-0 OPEN The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases Chen Chen1,2, Xiaolei Song1,3, Weixia Wei4,5, Huanzi Zhong 1,2,6, Juanjuan Dai4,5, Zhou Lan1, Fei Li1,2,3, Xinlei Yu1,2, Qiang Feng1,7, Zirong Wang1, Hailiang Xie1, Xiaomin Chen1, Chunwei Zeng1, Bo Wen1,2, Liping Zeng4,5, Hui Du4,5, Huiru Tang4,5, Changlu Xu1,8, Yan Xia1,3, Huihua Xia1,2,9, Huanming Yang1,10, Jian Wang1,10, Jun Wang1,11, Lise Madsen 1,6,12, Susanne Brix 13, Karsten Kristiansen1,6, Xun Xu1,2, Junhua Li 1,2,9,14, Ruifang Wu4,5 & Huijue Jia 1,2,9,11 Reports on bacteria detected in maternal fluids during pregnancy are typically associated with adverse consequences, and whether the female reproductive tract harbours distinct microbial communities beyond the vagina has been a matter of debate. Here we systematically sample the microbiota within the female reproductive tract in 110 women of reproductive age, and examine the nature of colonisation by 16S rRNA gene amplicon sequencing and cultivation. We find distinct microbial communities in cervical canal, uterus, fallopian tubes and perito- neal fluid, differing from that of the vagina. The results reflect a microbiota continuum along the female reproductive tract, indicative of a non-sterile environment. We also identify microbial taxa and potential functions that correlate with the menstrual cycle or are over- represented in subjects with adenomyosis or infertility due to endometriosis. The study provides insight into the nature of the vagino-uterine microbiome, and suggests that sur- veying the vaginal or cervical microbiota might be useful for detection of common diseases in the upper reproductive tract.
    [Show full text]
  • Vaginitis: General Information
    Sexual & Reproductive Health Vaginitis: General Information What is vaginitis? What are the symptoms? Vaginitis is a term that refers to a number of conditions, including infection, inflammation, and a change in flora (naturally occurring microorganisms) balance of the vagina. Generally, symptoms can include atypical vagina discharge (including change in the color, amount, and smell), itching, pain during vaginal sex or urination, and light vaginal bleeding. While each specific condition may have a different cause, there are a few common factors that contribute, including the use of antibiotics, spermicide, or douches; changes in hormone due to pregnancy or menopause; and sexual contact. Beyond those factors, wearing damp and tight clothes, having diabetes that is not adequately managed, having an IUD (intrauterine device), and using scented products near the vulva and vagina may also increase the risk of vaginitis. The most common conditions include: • Bacterial vaginosis is caused by an imbalance of the bacteria typically found within the vagina. • Yeast infections are a result of an overgrowth of naturally-occurring yeast (Candida albicans) in the vagina. • Trichomoniasis infection is due to a small parasite (protozoa) that is typically transmitted through sexual contact. • Increase in normal vaginal discharge not caused by an infection. Which might be linked to menstrual cycle, sexual activity, hormonal contraception, pregnancy, stress and diet changes. (This is sometimes called Cytolytic vaginosis) How is vaginitis diagnosed? How is it treated? Several conditions related to vaginitis will require a visit to a health care provider for diagnosis and treatment. The provider will ask questions about health history, including any previous vaginal or sexually transmitted infections.
    [Show full text]